Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Core Insights - Longeveron Inc. has launched a contract development and manufacturing business, which is expected to generate approximately $4-5 million in annual revenues [1][2] - The first manufacturing services contract has been signed with Secretome Therapeutics, focusing on neonatal mesenchymal stem cell-based therapeutics [1][2] - The company operates a state-of-the-art 15,000 square feet GMP facility, including 3,000 square feet of cleanroom space [1][2] Company Overview - Longeveron Inc. is a clinical stage biotechnology company specializing in regenerative medicines to address unmet medical needs [3] - The lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell therapy with potential applications across various disease areas [3] - Current pipeline indications include hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty [3] Strategic Partnerships - The partnership with Secretome Therapeutics aims to advance their portfolio of therapeutics, leveraging Longeveron's expertise in cellular therapy manufacturing [2] - The collaboration is expected to enhance Longeveron's experience and capabilities in the field of regenerative medicine [2] Market Potential - The demand for cellular therapy manufacturing is high, presenting significant opportunities for Longeveron to utilize its GMP facility's unused capacity [2] - The contract manufacturing services are positioned to support other pharmaceutical organizations in advancing their development programs without the need for their own manufacturing facilities [2]